Episode
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
- Podcast
- The Readout Loud
- Published
- Apr 23, 2026
- Duration seconds
- 2270
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/398-a-car-t-biotech-s-dramatic-turnaround-and-drugmakers-tactics-to-drive-more-scripts/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-readout-loud-1134305/398-a-car-t-biotech-s-dramatic-turnaround-and-drugmakers-tactics-to-drive-more-scripts.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Prescribery? We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. Venture capitalist Bryan Roberts joins us to discuss his firm’s investment in Kelonia Therapeutics, the CAR-T biotech that Eli Lilly just said it would buy for $3.25 billion. We also bring on our colleague Katie Palmer to talk through her story about pharma companies using bargain-basement telehealth providers to drive drug prescriptions and sales.